DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹20,878 Cr | ₹17,717 Cr | ₹15,937 Cr | ₹14,863 Cr | ₹14,619 Cr |
What is the latest Total Liabilities ratio of DIVIS LABORATORIES ?
| Year | Total Liabilities |
|---|---|
| Mar2026 | ₹20,878 Cr |
| Mar2025 | ₹17,717 Cr |
| Mar2024 | ₹15,937 Cr |
| Mar2023 | ₹14,863 Cr |
| Mar2022 | ₹14,619 Cr |
How is Total Liabilities of DIVIS LABORATORIES Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹20,878 Cr | 17.84 | |
| Mar2025 | ₹17,717 Cr | 11.17 | |
| Mar2024 | ₹15,937 Cr | 7.23 | |
| Mar2023 | ₹14,863 Cr | 1.67 | |
| Mar2022 | ₹14,619 Cr | - | |
Compare Total Liabilities of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹193,406.1 Cr | 7% | 10.2% | 3.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹468,458.0 Cr | 0.7% | 8.1% | 16% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹169,829.0 Cr | 2.5% | 11.3% | 49.6% | Stock Analytics | |
| CIPLA | ₹116,164.0 Cr | -0.3% | 4.1% | -3.3% | Stock Analytics | |
| MANKIND PHARMA | ₹105,174.0 Cr | 0.6% | 7% | 4.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,648.0 Cr | -3.2% | -3.9% | -3% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 7% |
10.2% |
3.7% |
| SENSEX | 0.9% |
2.2% |
-7.5% |
You may also like the below Video Courses